Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$143.80 USD

143.80
395,369

-2.27 (-1.55%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $143.81 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?

Smart Beta ETF report for NUMG

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

Style Box ETF report for QQQJ

Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Alnylam Pharmaceuticals (ALNY) Ahead of Earnings?

Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More

Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.

Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review

Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.

Geron (GERN) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Nuveen ESG MidCap Growth ETF (NUMG) a Strong ETF Right Now?

Smart Beta ETF report for NUMG

Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22

Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

VERA Dips Despite Positive Data From IgA Nephropathy Study

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy

Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.

Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report?

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.